1. A clinician argues that a single highly potent antiretroviral, dosed to achieve very high plasma levels, should durably suppress HIV without combination therapy. Integrating mutation rate, quasispecies structure, and fitness cost, which explanation best refutes this reasoning?
A) Potency is irrelevant because antiretrovirals act only on latently infected cells, where drug levels cannot be raised.
B) Monotherapy fails only when adherence is poor; with perfect adherence a single potent agent durably suppresses any RNA virus.
C) Because the high mutation rate continuously regenerates a quasispecies in which variants resistant to any single agent pre-exist, the drug eliminates wild-type while a pre-existing resistant variant — particularly a low-fitness-cost one — expands to dominance, so potency cannot compensate for a single-drug genetic barrier.
D) A single agent is sufficient because raising plasma levels proportionally lowers the viral mutation rate.
E) Combination therapy is needed only for DNA viruses, since RNA viruses are inherently drug-sensitive.
ANSWER: C
Rationale:
Option C is correct. The argument fails because three principles act together: the error-prone polymerase generates a high mutation rate, that rate sustains a quasispecies containing pre-existing variants resistant to any single agent, and a resistant variant with low fitness cost can expand rapidly once the drug clears wild-type. No achievable potency raises the genetic barrier of one drug enough to overcome a pre-existing resistant minority, which is why combination therapy is required.
Option A: Option A is incorrect. Monotherapy failure is driven by selection of pre-existing resistant variants in replicating virus, not by an inability to reach latent cells.
Option B: Option B is incorrect. Even with perfect adherence, single-agent pressure selects pre-existing resistance; adherence is not the only determinant.
Option D: Option D is incorrect. Plasma drug levels do not lower the viral mutation rate; the error-prone polymerase sets the rate independent of drug concentration.
Option E: Option E is incorrect. RNA viruses are precisely the ones requiring combination therapy because of their high mutation rates; they are not inherently drug-sensitive.
2. For a hypothetical emerging RNA virus, each single resistance mutation arises independently at a frequency of approximately 10^-5 per replication cycle, and daily production is about 10^9 virions. Applying the genetic-barrier principle, which regimen design is most likely to prevent emergence of preformed fully resistant variants?
A) A combination of three drugs targeting three independent viral proteins, lowering the probability of a preformed triple-resistant variant to roughly 10^-15, below the daily production rate.
B) A single drug given at maximal tolerated dose, since one preformed resistant variant arises at only 10^-5.
C) Two drugs that bind overlapping sites on the same viral protein, so one mutation confers resistance to both.
D) Sequential monotherapy, rotating one drug at a time to keep each individual mutation frequency at 10^-5.
E) A single drug combined with a host-directed agent that does not affect any viral protein, leaving the viral genetic barrier unchanged.
ANSWER: A
Rationale:
Option A is correct. With independent mutations at 10^-5 each, a preformed double-resistant variant arises at roughly 10^-10 and a triple-resistant variant at roughly 10^-15. Since 10^-15 is far below the daily production of 10^9 virions, three drugs against three independent targets make preformed fully resistant variants essentially nonexistent — the core genetic-barrier rationale.
Option B: Option B is incorrect. A single mutation at 10^-5 against 10^9 daily virions means thousands of resistant variants are produced daily, so monotherapy predictably fails.
Option C: Option C is incorrect. Overlapping binding on one protein lets a single mutation defeat both drugs, providing no multiplicative barrier.
Option D: Option D is incorrect. Sequential monotherapy exposes the virus to one drug at a time, selecting resistance to each in turn rather than requiring simultaneous multi-target resistance.
Option E: Option E is incorrect. A host-directed agent that touches no viral protein does not raise the viral genetic barrier, leaving the single-drug barrier in place.
3. The influenza M2 mutation S31N became globally fixed in untreated populations, whereas the HIV mutation M184V/I typically falls below detection after lamivudine is stopped. Integrating the concept of fitness cost, which explanation accounts for both observations?
A) S31N and M184V/I behave identically; the apparent difference reflects only differences in surveillance intensity between influenza and HIV.
B) Both mutations carry high fitness cost, so both should disappear without drug pressure; the persistence of S31N is unexplained by current models.
C) M184V/I has low fitness cost and therefore persists, while S31N has high fitness cost and is outcompeted — the opposite of what is observed.
D) S31N imposes near-zero fitness cost, so the resistant variant replicates as well as wild-type and spreads even without drug pressure, whereas M184V/I imposes substantial fitness cost, so wild-type outcompetes it once lamivudine is withdrawn.
E) Fitness cost applies only to DNA viruses, so neither outcome can be explained by fitness-cost reasoning.
ANSWER: D
Rationale:
Option D is correct. Fitness cost predicts both outcomes. S31N alters the adamantane binding site without impairing M2 channel function, so its near-zero fitness cost lets the variant replicate as efficiently as wild-type and spread without ongoing drug pressure. M184V/I reduces HIV reverse transcriptase replicative capacity substantially, so wild-type outcompetes it and the mutation resuppresses once lamivudine is removed.
Option A: Option A is incorrect. The divergence is a real fitness-cost difference, not an artifact of surveillance intensity.
Option B: Option B is incorrect. The two mutations differ in fitness cost; S31N is low-cost, which directly explains its persistence.
Option C: Option C is incorrect. This inverts the fitness costs of the two mutations.
Option E: Option E is incorrect. Fitness cost applies across viral types, including both influenza (RNA) and HIV (RNA), and explains both behaviors.
4. A heavily treatment-experienced HIV patient has a complex history with many prior regimens, and standard genotypic interpretation rules are giving ambiguous predictions because of multiple interacting mutations. Integrating the strengths and limits of the available tests, which testing approach is most appropriate?
A) Repeat standard Sanger genotyping only, since interacting mutations are always fully captured by genotype interpretation rules.
B) Phenotypic resistance testing, because directly measuring replication across drug concentrations resolves the net effect of multiple interacting mutations that genotypic rules struggle to predict in heavily treatment-experienced patients.
C) Co-receptor tropism testing alone, since tropism determines susceptibility to all antiretroviral classes.
D) Plasma drug-level monitoring only, because pharmacokinetic data substitute for resistance interpretation in complex cases.
E) No testing, because resistance in treatment-experienced patients cannot be characterized by any method.
ANSWER: B
Rationale:
Option B is correct. Phenotypic testing directly measures the virus's replication across drug concentrations and reports a net fold-change in IC50, which is especially valuable when multiple interacting mutations produce complex patterns that genotypic interpretation rules cannot reliably predict — the classic indication in heavily treatment-experienced patients, despite its longer turnaround and higher cost.
Option A: Option A is incorrect. Genotypic interpretation rules can be ambiguous precisely when many mutations interact, which is the situation described.
Option C: Option C is incorrect. Tropism testing governs maraviroc use only, not susceptibility to all classes.
Option D: Option D is incorrect. Drug levels assess adherence/exposure, not the resistance phenotype of a complex virus.
Option E: Option E is incorrect. Resistance in treatment-experienced patients is characterizable, and phenotyping is well suited to it.
5. While building a salvage regimen, a clinician notes that the current genotype (drawn on the failing regimen) shows no NNRTI mutations, yet an NNRTI mutation was documented on a genotype three years ago. Integrating the dynamics of resistance detection, how should the older result be weighed?
A) The older result should be discarded entirely, because only the most recent genotype has any clinical relevance.
B) The two results are contradictory and cannot both be valid, so neither should inform the regimen.
C) The absence of the mutation now proves the virus has reverted to full NNRTI susceptibility, so NNRTIs can be used freely.
D) The current genotype must be wrong, since resistance mutations never fall below detection once acquired.
E) The previously documented mutation likely persists as archived resistance below the current detection threshold and may re-emerge if that drug class is reintroduced, so the regimen should account for it as if still present.
ANSWER: E
Rationale:
Option E is correct. Resistance mutations can be driven below the detection threshold of standard genotyping when the selecting drug is absent, but they persist as archived resistance in proviral DNA or minority populations and can rapidly re-emerge if the class is reintroduced. Salvage planning should therefore treat the historically documented NNRTI mutation as still present and integrate all prior resistance results.
Option A: Option A is incorrect. Older resistance results remain relevant precisely because archived mutations are not erased; discarding them risks reusing a compromised class.
Option B: Option B is incorrect. Both results are valid; the discrepancy reflects detection dynamics, not contradiction.
Option C: Option C is incorrect. Non-detection does not prove reversion to susceptibility; the mutation may be archived below threshold.
Option D: Option D is incorrect. Mutations can and do fall below detection without the selecting drug, so the current genotype is not necessarily wrong.
6. A patient's HIV genotype shows accumulated thymidine analog mutations (TAMs) plus M184V. Integrating the two NRTI resistance mechanisms, which prediction about the nucleoside backbone is most accurate?
A) The TAMs (excision mechanism) confer broad NRTI cross-resistance that worsens as they accumulate, while M184V (discrimination mechanism) confers high-level lamivudine/emtricitabine resistance but partially restores susceptibility to certain agents and modestly reduces viral fitness.
B) Both TAMs and M184V act by discrimination, so the combination produces no excision-mediated cross-resistance.
C) M184V reverses the effect of all TAMs, fully restoring zidovudine and tenofovir activity.
D) TAMs act by discrimination and M184V by excision, so accumulation of TAMs has no effect on the broader NRTI class.
E) Neither mutation affects the nucleoside backbone, because NRTI resistance requires an integrase mutation as well.
ANSWER: A
Rationale:
Option A is correct. The two mechanisms produce distinct, integrable effects: TAMs work by excision (enhanced pyrophosphorolytic removal of the chain terminator) and accumulate to broaden NRTI cross-resistance, while M184V works by discrimination, conferring high-level lamivudine/emtricitabine resistance, modestly lowering viral fitness, and partially restoring susceptibility to some agents (for example, it can increase tenofovir and zidovudine susceptibility in the presence of TAMs).
Option B: Option B is incorrect. TAMs act by excision, not discrimination, so the combination does include excision-mediated cross-resistance.
Option C: Option C is incorrect. M184V does not fully reverse all TAMs or completely restore zidovudine and tenofovir activity.
Option D: Option D is incorrect. This inverts the mechanisms; TAMs are excision and do broaden NRTI cross-resistance as they accumulate.
Option E: Option E is incorrect. NRTI resistance arises within reverse transcriptase and does not require an integrase mutation.
7. When constructing a salvage regimen for multi-drug-resistant HIV, a principle is to assemble two to three fully active agents. Integrating INSTI generational differences with this counting principle, how should a second-generation INSTI such as dolutegravir be counted in a patient with no documented integrase mutations?
A) It cannot be counted, because all INSTIs are presumed compromised in any treatment-experienced patient.
B) It counts as a partially active agent only, because second-generation INSTIs require host kinase activation that is often impaired in salvage.
C) It should be excluded because integrase mutations are undetectable by standard genotyping.
D) It counts as a fully active agent, because second-generation INSTIs retain activity in the absence of documented integrase resistance and have a high genetic barrier requiring multiple mutations to lose susceptibility.
E) It counts as fully active only if combined with a first-generation INSTI to raise the barrier.
ANSWER: D
Rationale:
Option D is correct. In salvage planning, second-generation INSTIs (dolutegravir, bictegravir) are counted as fully active unless integrase resistance mutations are documented, because their high genetic barrier requires accumulation of two or more mutations to meaningfully reduce susceptibility. With no documented integrase mutations, dolutegravir contributes a full point toward the two-to-three fully active agent goal.
Option A: Option A is incorrect. INSTIs are not presumed compromised without documented resistance; that would discard a high-barrier option unnecessarily.
Option B: Option B is incorrect. INSTIs are not prodrugs requiring host kinase activation, so this rationale is mechanistically wrong.
Option C: Option C is incorrect. Integrase mutations are detectable by genotyping, and absence of documented mutations supports counting the drug as active.
Option E: Option E is incorrect. A second-generation INSTI is fully active on its own merits; pairing with a first-generation agent is not required.
8. A chronic hepatitis B virus (HBV) patient with documented prior lamivudine resistance now needs a high-barrier agent. Integrating the entecavir resistance pathway with this patient's mutational history, which choice and rationale is correct?
A) Re-treat with lamivudine, because resistance is reversible once the drug is briefly withdrawn.
B) Choose tenofovir, because the patient's pre-existing rtM204V/I plus rtL180M supplies two of the three mutations entecavir needs, sharply raising entecavir resistance risk, whereas tenofovir retains the highest barrier with no confirmed clinical resistance.
C) Choose entecavir, because prior lamivudine resistance has no bearing on the entecavir barrier.
D) Choose adefovir monotherapy, because it shares no resistance pathway with entecavir or tenofovir.
E) Choose telbivudine, because L-nucleoside analogs are unaffected by rtM204V/I.
ANSWER: B
Rationale:
Option B is correct. Entecavir resistance requires rtM204V/I plus rtL180M plus one additional mutation; a lamivudine-resistant virus already carries the first two, so only one more is needed, sharply elevating entecavir resistance risk. Tenofovir, with the highest barrier of any approved HBV agent and no confirmed clinical resistance, is therefore preferred in patients with prior lamivudine exposure.
Option A: Option A is incorrect. Lamivudine resistance mutations persist (archived), so re-treatment with lamivudine is not appropriate.
Option C: Option C is incorrect. Prior lamivudine resistance substantially lowers the entecavir barrier, so it does bear on the choice.
Option D: Option D is incorrect. Adefovir is a low-barrier agent and not the high-barrier choice here.
Option E: Option E is incorrect. Telbivudine is an L-nucleoside analog cross-affected by rtM204V/I, so it is compromised in this patient.
9. A treatment-naive hepatitis C virus (HCV) patient is to start sofosbuvir-velpatasvir, and the clinician questions whether baseline resistance-associated substitution (RAS) testing is needed. Integrating the resistance-barrier concept with the role of re-treatment testing, which statement is most accurate?
A) Baseline RAS testing is mandatory for all naive patients, because any NS5A substitution abolishes cure.
B) RAS testing is never useful in HCV at any point, because the virus does not develop clinically relevant resistance.
C) Baseline RAS testing is not routinely required for this naive patient because the high-barrier NS5B nucleotide inhibitor sofosbuvir anchors the regimen and cure rates exceed 95% even with baseline NS5A or NS3 substitutions, yet NS5A RAS testing becomes useful for re-treatment after prior failure because NS5A substitutions persist for years.
D) Baseline testing is unnecessary because HCV, like HBV, has an extremely low mutation rate and rarely generates substitutions.
E) RAS testing should replace measurement of cure (sustained virologic response), since genotype predicts outcome perfectly.
ANSWER: C
Rationale:
Option C is correct. For most treatment-naive patients, the exceptionally high-barrier NS5B nucleotide inhibitor sofosbuvir anchors pangenotypic regimens so that cure rates exceed 95% even when baseline NS5A or NS3 substitutions are present, making routine baseline RAS testing unnecessary. However, because NS5A substitutions persist for years, NS5A RAS testing does become useful when planning re-treatment after a prior failure.
Option A: Option A is incorrect. NS5A substitutions do not abolish cure in naive patients on a sofosbuvir-anchored regimen, so universal baseline testing is not mandated.
Option B: Option B is incorrect. RAS testing has a defined role in re-treatment, so it is not useless at all points.
Option D: Option D is incorrect. HCV actually has one of the highest mutation rates in virology; the reason testing is skipped is the sofosbuvir anchor, not low mutation rate.
Option E: Option E is incorrect. Sustained virologic response remains the measure of cure; genotype does not predict outcome perfectly and cannot replace it.
10. A transplant recipient with refractory cytomegalovirus (CMV) has genotyping returned. Integrating the consequences of UL97 versus UL54 mutations, which interpretation correctly links genotype to drug choice?
A) An isolated UL97 mutation confers ganciclovir resistance while foscarnet, cidofovir, and maribavir remain options; an added UL54 mutation can extend cross-resistance to foscarnet and/or cidofovir depending on its polymerase-domain location, making the combined UL97 plus UL54 genotype the most difficult to treat.
B) An isolated UL97 mutation abolishes activity of foscarnet and cidofovir as well as ganciclovir, leaving no treatment option.
C) A UL54 mutation restores ganciclovir activity, so identifying it allows ganciclovir to be continued unchanged.
D) Maribavir is contraindicated whenever any UL97 mutation is present, because maribavir shares ganciclovir's exact binding site.
E) UL97 and UL54 mutations are functionally interchangeable, so the genotype does not influence drug selection.
ANSWER: A
Rationale:
Option A is correct. An isolated UL97 mutation impairs ganciclovir activation only, so foscarnet and cidofovir (which do not need UL97) and maribavir (which inhibits UL97 at a distinct site, retaining activity against many UL97 mutations) remain options. An added UL54 polymerase mutation can confer cross-resistance to foscarnet and/or cidofovir depending on its location, so combined UL97 plus UL54 is the most clinically challenging genotype.
Option B: Option B is incorrect. An isolated UL97 mutation does not abolish foscarnet and cidofovir activity; they remain active.
Option C: Option C is incorrect. UL54 mutations add resistance and do not restore ganciclovir activity.
Option D: Option D is incorrect. Maribavir binds UL97 at a site distinct from ganciclovir and retains activity against many UL97 mutations, so it is not categorically contraindicated.
Option E: Option E is incorrect. UL97 and UL54 mutations have different consequences and clearly do influence drug selection.
11. Two immunocompromised patients have acyclovir-resistant herpes simplex virus (HSV). Patient 1 has a thymidine kinase (TK)-null genotype; Patient 2 has a viral DNA polymerase (UL30) mutation. Integrating the two resistance mechanisms, which prediction about foscarnet is correct?
A) Foscarnet will fail in both patients, because acyclovir resistance by any mechanism confers automatic foscarnet cross-resistance.
B) Foscarnet will fail in Patient 1 (TK-null) but succeed in Patient 2 (polymerase mutation).
C) Foscarnet activity cannot be predicted from the mechanism in either patient.
D) Foscarnet is expected to remain active in Patient 1 (TK-null), because foscarnet does not require viral TK, but may be compromised in Patient 2 if the DNA polymerase mutation also affects the foscarnet binding region.
E) Foscarnet will succeed in both patients regardless of mechanism, because polymerase mutations never affect foscarnet.
ANSWER: D
Rationale:
Option D is correct. Foscarnet acts directly on the viral DNA polymerase and does not need viral TK, so it remains active against TK-null virus (Patient 1). In Patient 2, a DNA polymerase mutation can confer cross-resistance to foscarnet if it alters the pyrophosphate-binding region the drug targets, so foscarnet may be compromised depending on the specific mutation.
Option A: Option A is incorrect. TK-null resistance does not confer foscarnet cross-resistance; foscarnet remains active there.
Option B: Option B is incorrect. This inverts the mechanisms — foscarnet works in the TK-null patient, not fails.
Option C: Option C is incorrect. The mechanism does predict foscarnet behavior, as detailed above.
Option E: Option E is incorrect. Polymerase mutations can affect foscarnet, so universal success cannot be assumed in Patient 2.
12. Considering acyclovir-resistant HSV, ganciclovir-resistant cytomegalovirus (CMV), and nirmatrelvir- or remdesivir-resistant SARS-CoV-2 together, a clinician wants to identify which patient faces the highest risk of antiviral resistance emergence. Integrating the unifying principle, which patient is at greatest risk and why?
A) A healthy adult with a brief, fully suppressive, adherent course of antiviral therapy, because rapid suppression paradoxically drives resistance.
B) A vaccinated patient, because vaccine-induced antibodies select escape mutations at antiviral drug targets.
C) A pediatric patient with normal immune function, because immature drug clearance produces high drug levels that select resistance.
D) An immunocompetent patient with an acute self-limited infection, because high peak viral load guarantees resistance.
E) A severely immunocompromised patient on prolonged antiviral therapy, because the inability to clear virus immunologically combined with sustained drug selection pressure — without the immune co-factor that eliminates residual replication — is the shared driver of resistance across all three pathogens.
ANSWER: E
Rationale:
Option E is correct. Across herpesviruses and SARS-CoV-2, resistance emerges preferentially in severely immunocompromised patients on prolonged therapy. The unifying mechanism is sustained drug selection pressure operating without immune clearance of residual low-level replication, so the resistant variant is not eliminated as it would be in an immunocompetent host.
Option A: Option A is incorrect. Brief, fully suppressive, adherent therapy lowers resistance risk; rapid suppression does not drive resistance.
Option B: Option B is incorrect. Vaccine antibodies target surface antigens, not antiviral drug-binding sites, and do not drive antiviral resistance.
Option C: Option C is incorrect. Resistance risk is tied to prolonged therapy in immune-deficient hosts, not to pediatric drug clearance.
Option D: Option D is incorrect. Immunocompetent hosts clear residual virus immunologically and are at low resistance risk despite high peak viral loads.
13. A national pandemic-preparedness committee is designing an antiviral resistance strategy for a future emerging RNA virus. Integrating the lessons from HIV, HCV, and influenza resistance, which combination of measures best embodies sound resistance-aware planning?
A) Deploy a single most-potent antiviral as monotherapy nationwide, defer surveillance until resistance becomes widespread, and stockpile only that one agent for simplicity.
B) Establish resistance surveillance infrastructure before widespread deployment, prioritize combination therapy that targets mechanistically distinct viral proteins for high-risk and immunocompromised patients, maintain a mechanistically diverse stockpile, and validate resistance interpretation algorithms before clinical rollout.
C) Treat only immunocompetent patients, since they are the principal source of resistance emergence, and rely on dose escalation of one agent to outpace resistance.
D) Rotate single agents sequentially across the population to keep each individual mutation frequency low, avoiding the complexity of combinations.
E) Withhold all antivirals until a vaccine is available, because antiviral resistance cannot be managed under any circumstances.
ANSWER: B
Rationale:
Option B is correct. Sound resistance-aware preparedness integrates the established lessons: build surveillance before deployment (not after), use mechanistically distinct combination therapy especially for high-risk and immunocompromised patients who drive resistance emergence, keep a mechanistically diverse stockpile to avoid single-point-of-failure resistance, and validate interpretation algorithms before clinical use.
Option A: Option A is incorrect. Nationwide monotherapy, deferred surveillance, and a single-agent stockpile are exactly the failure modes the resistance principles warn against.
Option C: Option C is incorrect. Immunocompromised patients, not immunocompetent ones, are the principal source of resistance, and dose escalation of one agent does not raise the genetic barrier.
Option D: Option D is incorrect. Sequential monotherapy selects resistance to each agent in turn rather than requiring simultaneous multi-target resistance.
Option E: Option E is incorrect. Antiviral resistance is manageable with combination therapy and surveillance; withholding all antivirals is neither necessary nor justified.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.